Form SC 13D/A Valeant Pharmaceuticals Filed by: Pershing Square Capital Management, L.P.
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Buy Valeant Pharmaceuticals (VRX) Ahead of Investor Day Catalyst - Guggenheim
November 24, 2015 8:02 AM ESTGuggenheim analyst Louise Chen reiterated a Buy rating and $195 on Valeant Pharmaceuticals (NYSE: VRX) saying the stock has bottomed and multiple expansion will drive shares higher. Chen recommends buying ahead of the December 16, 2015 investor day catalyst.
"Concerns regarding high-priced drugs and specialty pharmacies have weighed on VRX shares since mid-September,... More
Pershing Square Capital Affirms Lifting Valeant Pharma (VRX) Stake to 9.9%
November 23, 2015 5:28 PM ESTPershing Square Capital Management, L.P., the investment manager for Pershing Square Holdings, Ltd. has updated its Schedule 13D with the United States Securities and Exchange Commission, disclosing that various funds it manages increased their beneficial ownership of Valeant Pharmaceuticals International, Inc. (NYSE: VRX), to 9.9% of shares outstanding.
... MoreAckman's Pershing Square Capital Raises Stake in Valeant Pharmaceuticals (VRX) to 9.9%
November 23, 2015 5:17 PM ESTIn an amended 13D filing on Valeant Pharmaceuticals (NYSE: VRX), Bill Ackman's hedge fund Pershing Square Capital disclosed a 9.9%, or 34,118,551 share, stake in the company. This is up 75.20% from the 19,473,933 shares held at the end of the latest quarter ending September 30, 2015.
For more notable holders of Valeant Pharmaceuticals stock click here. For more information on Pershing Square Capital click... More
Pershing Square Capital Raises Stake in Valeant Pharma (VRX) to 9.9%
November 23, 2015 5:16 PM ESTIn a 13D filing on Valeant Pharma (NYSE: VRX), hedge fund Pershing Square Capital disclosed a 9.9%, or 34,118,551 share, stake in the company. This is up 75.20% from the 19,473,933 shares held at the end of the latest quarter ending September 30, 2015.
For more notable... More
